2015 American Society of Clinical Oncology Annual Meeting*

Download All
May 29-June 2, 2015; Chicago, Illinois
Thomas H. Cartwright, MD, reviews data from key gastrointestinal cancer presentations from the 2015 clinical oncology meeting in Chicago.
Thomas H. Cartwright, MD

Gastrointestinal Cancers

Addition of SIRT to chemotherapy first-line treatment of metastatic CRC did not improve overall PFS or ORR, but substantially reduced the risk of disease progression in the liver.

Released: June 1, 2015

Highest baseline vitamin D levels associated with OS and PFS improvement regardless of chemotherapy backbone and biologic assignment.

Released: June 1, 2015

The largest cohort ever to examine the effects of aspirin as secondary prevention reveals that aspirin independently reduces the risk of both CRC-specific mortality and all-cause mortality.

Released: June 1, 2015

Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.

Released: June 2, 2015

This slideset covers the final and subgroup results of the INTEGRATE phase II trial of regorafenib in refractory advanced gastroesophageal cancer as presented at the 2015 ASCO meeting.

Released: June 1, 2015

In this pilot study, mFOLFIRINOX and chemoradiation were shown to be tolerable and allowed most patients to go on to resection.

Released: June 3, 2015

In this CME-certified downloadable slideset, Thomas H. Cartwright, MD, reviews key studies on the management of GI cancers. Review the slide notes for Dr. Cartwright’s commentary.

Thomas H. Cartwright, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 31, 2015 Expired: No longer available for credit

Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.

Released: May 31, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.